From Sea to Shining Sea: Generic Savings State by State
Safe, reliable generic prescription drugs enable Americans to save money at the pharmacy counter. The government saves big, too, on medicine for seniors and low-income people. In 2017, overall savings came to $265 billion. AAM’s annual generic drug savings and access report presents the independent findings of IQVIA regarding the savings that our companies bring […]
BCBS: It’s time to CREATE more choices & lower drug prices
Biologic drugs are pushing the boundaries of medicine, and their potential to benefit patients with unmet medical needs has never been more promising. For example, researchers are using a viral therapy to treat advanced melanoma by targeting only cancerous cells, and prompting the patient’s immune system to attack them as well. But all too often […]
$13.4 Billion a Year! Brand “Shenanigans” Are Costing Patients More Than Ever
When a brand-name prescription drug’s market exclusivity (its monopoly) and patents expire, generic and biosimilar medicines become available, the savings begin and patients win. That’s how the system is supposed to work. However, brand-name pharmaceutical companies have increasingly abused FDA’s safety programs (Risk Evaluation and Mitigation Strategies, or REMS) and other manufacturer-imposed restricted distribution of […]
New Study Finds Patients, Government and Insurance Lose $13.4B in Potential Savings By Brand Drug Companies’ Abuses
Study Finds Costs of Brand Abuses Have Exploded in 4 Years, Harming Patient Access to Affordable Generic and Biosimilar Medicines WASHINGTON DC (September 4, 2018) – Continued efforts to delay patient access to biosimilar and generic drugs have an increasing negative impact on patients, according to an updated report released today by Matrix Global Advisors […]
Why Seniors Are Paying More as Drug Prices Fall
As federal and state policymakers grapple with how to lower prescription drug prices, they should work to ensure that patients, particularly seniors, have greater access to and realize the full benefit of lower-priced generic drugs. Increasingly, Medicare Part D plans are putting generic drugs into higher formulary tiers to compensate for escalating brand-name drug prices. […]
Patients Can See Their Savings
America’s patients can now see how much they save by treating their health conditions using generic drugs thanks to new data pulled from this year’s Generic Access and Savings Report in the United States. For the first time ever, the Association for Accessible Medicines (AAM) is releasing savings data for 20 common patient conditions, demonstrating the […]
AAM Statement on Importation Task Force
WASHINGTON DC (July 19, 2018) – Secretary Azar testified on June 26 before the Senate Finance Committee, policy makers should examine whether the U.S. is “underpaying for and under-reimbursing for generics. We need a strong, robust generic market. We may be driving those prices so low that we’re creating manufacturing anomalies that lead to sole-source […]
Highlights from Craig Burton on the Newly Released 2018 Generic Drug Access & Savings Report
AAM’s VP Policy Craig Burton shares the release of the 2018 Generic Drug Access & Savings in the U.S. report, which focused this year on savings from patient utilization of generic drugs. The report highlights 3 important findings: 9 out of every 10 prescriptions in the U.S. are generic drugs 93% of generic prescriptions are […]
AAM Provides Comments in Response to Administration’s Blueprint on Drug Pricing
Generic and Biosimilars Competition Drives Lower Prices and Reduced Out-of-Pocket Costs for Patients Washington DC (July 16, 2018)—The Association for Accessible Medicines (AAM) and the Biosimilars Council have today filed comments on the Trump Administration’s drug pricing blueprint. The Blueprint identifies four overarching goals for lowering drug prices: increasing competition; better negotiation; creating incentives for […]
Generic Drug Competition Lowers Prescription Cost to $6 on Average, Study Finds
Generic Pharmaceutical Industry Releases 10th Annual Access and Savings Report Shows Savings from Generic and Biosimilar Medicines at Risk WASHINGTON DC (July 10, 2018) – Today, the Association for Accessible Medicines (AAM) released its “Generic Access and Savings Report in the United States 2018,” which finds that 93 percent of generic prescriptions are filled at $20 […]
AAM Statement in Response to Secretary Azar’s Testimony Before Senate Finance Committee
WASHINGTON DC (June 26, 2018) – Secretary Azar’s testimony today highlighted two very important issues when it comes to reducing prescription drug prices in the United States. First, Secretary Azar noted that anticompetitive tactics used by brand-name manufacturers distort the market and keep prices artificially high. Notably, Secretary Azar endorsed the aims of the bipartisan CREATES […]
NYT: Generic Drug Prices Are Falling, but Are Consumers Benefiting?
Chip Davis has been out speaking with the media about the importance of generic and biosimilar medicines to patients and our economy. He is shining a light on the need to remedy anti-competitive roadblocks facing generics and biosimilars before they make it to market, and the challenges approved drugs meet when presented by consolidation on […]
